Navigation Links
Charles Saldarini is New CEO of Sentrx
Date:4/16/2009

Sentrx, the leading provider of drug safety services to the life sciences industry, has appointed Charles T. Saldarini as Chief Executive Officer and Chairman of the Board. Saldarini is a proven leader in the field of biopharmaceutical outsourcing services. He spent 18 year at PDI, Inc., rising to the position of CEO as he established the company as the leader in contract sale services.

Little Falls, NJ (PRWEB) April 16, 2009 -- Sentrx, the leading provider of drug safety services to the life sciences industry, is pleased to announce the appointment of Charles T. Saldarini as Chief Executive Officer and Chairman of the Board.

"Charles Saldarini is a proven leader in biopharmaceutical services and an innovator in the field of outsourcing," said John Martinson, Managing Partner of Edison Venture Capital, the primary investor in Sentrx. "His vision will bring Sentrx to its next level of growth."

Saldarini began his career as a Sales Representative for Merrill-Dow Pharmaceuticals. He soon moved to the entrepreneurial environment of PDI, Inc. (NASDAQ: PDII), one of the industry's first contract sales organizations, at the company's inception. Saldarini established PDI as a strategic option for biopharmaceutical companies. He built a highly professional contract sales service that was the first to match the industry standards for quality and effectiveness while offering a significantly reduced cost per representative. His passion to create new market approaches and expand service offerings allowed PDI to achieve high levels of client acquisition, retention and satisfaction.

During his 18-year tenure, Saldarini drove its growth in annual revenue from $1M to $365M. Saldarini's leadership enabled a successful public capitalization in 1998, followed by multiple acquisitions and strategic partnerships. At his departure as Vice Chairman and CEO, PDI was debt free, held over $100M in cash and was well positioned as a complete commercial services provider.

"I am excited to join an organization at the forefront of drug safety and risk management," said Charles Saldarini. "The 25% growth in revenue Sentrx achieved in 2008 demonstrates that clients trust our capabilities. My role is to expand that trust so that we maximize the company's opportunities in the market, creating an outstanding environment for our employees and excellent value for our shareholders."

"I have been interested in the business model of Sentrx since outsourcing drug safety to the firm at a previous employer," commented Gregory Fiore, MD, Senior Director of Pharmacovigilance at Schering-Plough Research Institute. "Charles Saldarini impresses me as a great leader who will transform the company to deliver a clear vision of the future of drug safety."

Saldarini earned a Bachelor of Arts with Honors in Political Science and Telecommunications from Syracuse University. Currently, he serves on the boards of Cadient Group, Octagon Clinical Research Solutions and Informed Medical Communications. Additionally, Saldarini is active in the field of education, serving on the Board of Visitors at Syracuse University, the Board of Advisors at Anisfield School of Business at Ramapo College, and his local school board.

About Sentrx
Sentrx is a leading provider of technology-enabled solutions and services for global drug safety. Its mission is to help pharmaceutical, biotechnology, medical device, and consumer health companies document the safety profile of their products during clinical development and post-approval, enabling them to minimize risks and maximize benefits. Through its multilingual Safety Response Center in Little Falls, NJ, Sentrx delivers a unique combination of highly skilled people, exclusive technology, and best practices in drug safety monitoring. To learn more about Sentrx, please call 1-888-399-8032, extension 261, or follow the links below.
        
View the Sentrx movie
Visit the Sentrx website

###

Read the full story at http://www.prweb.com/releases/2009/04/prweb2321324.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Informed Medical Communications Appoints Charles T. Saldarini to Board of Directors
2. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
3. Dr. Charles A. Sims of California Cryobanks Family Cord Blood Services Named to National Stem Cell Advisory Council
4. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
5. Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology
6. Charles C. Harwood, Jr., Joins Cellectar, Inc.s Board of Directors
7. Dr. Charles Sanders to Become Lead Director of Epiphany Biosciences
8. GEN Joins Charles Darwin 2009 Celebration
9. Microbia PE Adds Nutritional Ingredient Industry Veteran Charles Walton to Senior Management Team
10. Sentrx Exits 2008 with Strong Growth
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Charles Saldarini is New CEO of Sentrx
(Date:10/12/2017)... ... October 12, 2017 , ... ... multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® test, ... clinically significant acute bacterial and viral respiratory tract infections by testing the ...
(Date:10/11/2017)... CA (PRWEB) , ... October 11, 2017 , ... ... upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding the ... system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
Breaking Biology Technology:
(Date:10/4/2017)...  GCE Solutions, a global clinical research organization (CRO), announces the ... on October 4, 2017. Shadow is designed to assist medical writers ... 0070 of the European Medicines Agency (EMA) in meeting the requirements ... ... ...
(Date:8/15/2017)... ivWatch LLC , a medical device company focused on improving the ... its ISO 13485 Certification, the global standard for medical device quality ... ... device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it validates ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
Breaking Biology News(10 mins):